Forma Therapeutics (Cambridge, MA) a development-stage screening and discovery company focused on cancer therapies, closed a $25.5M Series B financing. Participants include Lilly Ventures, Novartis Option Fund and Bio*One Capital.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

arGEN-X (Netherlands) a development-stage biopharmaceutical company focused on a monoclonal antibody platform with potential indications in autoimmunity, oncology and bone disease, closed a $4.5M Series A financing, bring total round proceeds to $18.3M. Participants have included Credit Agricole Private Equity, Forbion Capital Partners, Life Science Partners, KBC Private Equity, BioGeneration Ventures, Erasmus MC Biomedical Fund, [...]

AmVac (Switzerland) a development-stage vaccine company focused on vaginitis , BPH and RSV, closed a $2.8M Series A financing bringing the total round to $4M. Participants include Venture+ and Co Fonds 2.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Morvus Technology (United Kingdom) a preclinical-stage pharmaceutical company focused on prodrug and anti-angiogenic oncology approaches, closed a $3.3M Series A financing. Participants were not identified.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

ReVance Therapeutics (Mountain View, CA) a clinical-stage biopharmaceutical company focused on dermatology and aesthetic medicine, closed a $25.6M Series D financing. Particpants have included Essex Woodlands Health Ventures, Vivo Ventures, Technology Partners, Shepherd Ventures, Palo Alto Investors, Bio*One Capital and Pac-Link Venture.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

CalciMedica (La Jolla, CA) a preclinical-stage small molecule company focused on autoimmune and inflammatory via the inhibition of calcium release-activated calcium (CRAC) channels, closed a $5M Series C financing, bringing the total round up to $9M. Participants include Biogen Idec, Sanderling Ventures and SR One.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Sinocom Pharmaceutical (China) a commercial-stage manufacturer of active pharmaceutical ingredients for traditional Chinese medicinal pharmaceutical companies, closed a $15M Series A financing. Participants include Seavi Advent Private Equity.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Pfenex (San Diego, CA) a commercial-stage biotechnology company focused on recombinant protein expression for a broad range of applications including therapeutic proteins, vaccines, research, reagents and biosimilars, closed a $24M Series A financing. Participants include Signet Healthcare Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Circassia (United Kingdom) a clinical-stage specialty biopharmaceutical focused on therapeutic T-cell vaccines for allergies and organ transplant rejection, closed a $25M Series C financing. Participants include Imperial Innovations, Invesco Perpetual and Lansdowne Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Savara Pharmaceuticals (Austin, TX) a development-stage Dry powder and nebulizer-based drug delivery solution, closed a $1.4M Series A financing. Participants were not identified.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb